Using levofloxacin injections to treat skin leishmaniasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of intralesional levofloxacin 0.5% solution as a local injection for treating cutaneous leishmaniasis. In an open-label single-arm design, patients with cutaneous leishmaniasis lesions receive weekly injections of levofloxacin for up to six weeks, with follow-up for 90 days or until lesions are cured. The study aims to provide a safer and more cost-effective alternative to traditional systemic therapies for patients with localized forms of the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis and patients ranging in age from 20 to 75 years old.

Exclusion Criteria:

* Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study and patients on prolonged corticosteroid therapy.

Where it's running

• Mustansiriyah University
  Baghdad, Iraq Recruiting

Study contacts

• Study coordinator: Hayder Adnan Fawzi, PhD
• Email: haider-pharm@almustafauniversity.edu.iq
• Phone: 07800106177

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using metronidazole injections to treat skin lesions from leishmaniasis

  This study is testing if weekly injections of metronidazole can help people with skin lesions from leishmaniasis heal faster.

  Recruiting Phase 2 Al-Mustafa University College · Baghdad · NCT06798415

• Ciprofloxacin injections for treating skin leishmaniasis

  This study is testing if ciprofloxacin injections can effectively treat skin leishmaniasis compared to the standard treatment with sodium stibogluconate.

  Recruiting Phase 2 Al-Mustafa University College · Baghdad · NCT06798402

• Using thermotherapy at health centers to treat skin leishmaniasis in Ethiopia

  This study tests whether thermotherapy using the ThermoMed device can be feasibly used in primary care to treat cutaneous leishmaniasis in Ethiopia and sees how well it works for people in the Sodo area.

  Recruiting Armauer Hansen Research Institute, Ethiopia · Addis Ababa · NCT06746350

• Immunogenicity screening of Leishmania vaccine candidate antigens in Ethiopian patients

  This study tests whether six Leishmania vaccine candidate antigens can trigger T-cell responses in patients with cutaneous or visceral leishmaniasis.

  Recruiting at 2 sites Institute of Tropical Medicine, Belgium · Addis Ababa and 1 other locations · NCT07783243

• Pediatric leishmaniasis in Italy: clinical and treatment patterns

  This project will collect medical information to see how leishmaniasis presents and is treated in children under 18 in Italy.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Tuscany · NCT07504757

• Arnica tincture for treating cutaneous leishmaniasis

  This test will see if applying arnica tincture to skin lesions helps heal cutaneous leishmaniasis in people aged 12 and older.

  Recruiting Phase 3 Universidad de Antioquia · Medellín, Antioquia · NCT06822478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.